Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(1)
DRUG(1)
2 unique interventions2 categories

Analytics

Trial Phases

Phase 11

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT00741234Phase 1Completed
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
Hematologic MalignanciesMyelodysplastic SyndromeSolid Tumors
Principalinvestigator

Research Network

Collaboration Network

12 collaborators·17 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

National University Hospital, Singapore

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Charles Chuah, M.D.

Singapore General Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

Hematologic NeoplasmsMyelodysplastic SyndromesSolid Tumors

Worked with same sponsors:

S*BIO
Collaborated on 1 trial
Similarity Score34%

George Wilding, M.D.

University of Wisconsin, Madison

Moderately Similar
1 trials

Shared therapeutic areas:

Hematologic NeoplasmsMyelodysplastic SyndromesSolid Tumors

Worked with same sponsors:

S*BIO
Collaborated on 1 trial
Similarity Score34%

Han Chong Toh, M.D.

National Cancer Center

Moderately Similar
1 trials

Shared therapeutic areas:

Hematologic NeoplasmsMyelodysplastic SyndromesSolid Tumors

Worked with same sponsors:

S*BIO
Collaborated on 1 trial
Similarity Score34%

Guillermo Garcia-Manero, MD

M.D. Anderson Cancer Center

Moderately Similar
18 trials

Shared therapeutic areas:

Myelodysplastic SyndromesHematologic NeoplasmsSolid Tumors

Worked with same sponsors:

S*BIO
Collaborated on 1 trial
Similarity Score34%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Hematologic NeoplasmsMyelodysplastic Syndromes
Similarity Score20%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Hematologic NeoplasmsSolid Tumors
Similarity Score20%

Yifan Zhai, MD, PhD

Ascentage Pharma Group Inc.

Related
14 trials

Shared therapeutic areas:

Hematologic NeoplasmsMyelodysplastic Syndromes
Similarity Score20%

Qifa Liu

Nanfang Hospital, Southern Medical University

Related
33 trials

Shared therapeutic areas:

Myelodysplastic SyndromesHematologic Neoplasms
Similarity Score20%

Farhad Ravandi-Kashani, MD

M.D. Anderson Cancer Center

Related
14 trials

Shared therapeutic areas:

Myelodysplastic SyndromesHematologic Neoplasms
Similarity Score20%

Richard W Childs, M.D.

National Heart, Lung, and Blood Institute (NHLBI)

Related
15 trials

Shared therapeutic areas:

Hematologic NeoplasmsMyelodysplastic Syndromes
Similarity Score20%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT00741234Phase 1PrincipalInvestigator

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Hematologic MalignanciesMyelodysplastic SyndromeSolid Tumors
Completed

All 1 trials loaded